Therapeutic options for the treatment of colorectal cancer following 5-fluorouracil failure.
Therapeutic options after failure of 5-fluorouracil (5-FU) for the treatment of colorectal cancer include regional treatments, different 5-FU-based regimens, and different chemotherapy regimens. Of the regional treatments, resection of hepatic metastases is the most satisfactory because of the potential for long-term survival; however, the number of candidates for this option is limited. Responses are possible if 5-FU is administered by prolonged infusion, but the addition of other chemotherapeutic agents (eg, nitrosoureas, mitomycin C, or cisplatin) is less likely to induce objective responses. The new topoisomerase I inhibitor irinotecan has promising activity in patients with metastatic colorectal cancer. Depending on the status of the patient population, objective response rates of 15% to 30% have been reported in patients with colorectal cancer that has progressed or rapidly recurred following 5-FU-based treatment.
Henderson
C A
CA
Peachtree Hematology & Oncology, Atlanta, GA 30309, USA.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000473:pathology / Q000628:therapy*; D003452:Cryosurgery; D004621:Embolization, Therapeutic; D005472:Fluorouracil / Q000008:administration & dosage; D006498:Hepatectomy; D006801:Humans; D007261:Infusions, Intra-Arterial; D015552:Injections, Intralesional; D000077146:Irinotecan; D008113:Liver Neoplasms / Q000556:secondary* / Q000628:therapy*; D059004:Topoisomerase I Inhibitors; D017211:Treatment Failure; D016597:Trimetrexate / Q000008:administration & dosage
D059004:Topoisomerase I Inhibitors; D000077146:Irinotecan; D005472:Fluorouracil; D016597:Trimetrexate; D002166:Camptothecin